KRAS and familial pancreatic carcinoma: KRAS is the most commonly mutated oncogene in pancreatic cancer and represents one of the earliest alterations observed in pancreatic intraepithelial neoplasia (Pan IN) (Figure 2), where KRAS mutations lead to the activation of downstream effectors, driving various pro-tumorigenic processes (11).